ContraFect Corporation, a development stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin for the treatment of Staph aureus bacteremia; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic influenza infections. The company was 2008 and is headquartered in Yonkers, New York.